NCT03564912View on ClinicalTrials.gov

Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

August 12, 2018

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions

Colorectal Cancer

Interventions

DRUG

Capecitabine Oral Tablet [Xeloda]

2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w

Trial Locations (1)

310000

First afflicated hospital of zhejiang university, Hangzhou

All Listed Sponsors

lead

Zhejiang University

OTHER

NCT03564912 - Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC | Biotech Hunter | Biotech Hunter